Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (ABBV) is a global biopharmaceutical leader driving innovation in immunology, oncology, and neuroscience therapies. This page provides real-time access to AbbVie's official press releases, regulatory milestones, and strategic developments.
Investors and industry professionals will find a curated collection of earnings reports, FDA approval updates, clinical trial results, and partnership announcements. Our comprehensive resource eliminates the need to track multiple sources, offering verified information directly from corporate communications and trusted financial publications.
Key content includes updates on AbbVie's R&D pipeline, mergers & acquisitions like the Allergan integration, patent developments, and market expansion initiatives. All materials are organized chronologically for efficient analysis of the company's trajectory.
Bookmark this page for streamlined monitoring of AbbVie's operational and financial performance. Check back regularly to stay informed about developments impacting one of the pharmaceutical sector's most influential innovators.
AbbVie announced significant findings on its investigational drugs at the UEG Week Virtual 2021, running from October 3-5. The company will present 13 abstracts, including late-breaking studies on risankizumab (SKYRIZI) for Crohn's disease and upadacitinib (RINVOQ) for ulcerative colitis. Key results from pivotal Phase 3 studies showed upadacitinib's efficacy in symptom control and clinical remission at week 52. Additionally, data highlighting the quality of life improvements for IBD patients will be shared. AbbVie aims to enhance treatment standards in IBD management.
AbbVie has shared new Phase 3 data analyses from the KEEPsAKE-1 and KEEPsAKE-2 studies, detailing the efficacy of risankizumab (SKYRIZI®) in treating adults with active psoriatic arthritis over one year. At the 2021 EADV Virtual Congress, results showed significant patient responses, with 70% and 58% achieving ACR20 response in KEEPsAKE-1 and KEEPsAKE-2, respectively. Furthermore, 76% achieved resolution of dactylitis. The safety profile remained consistent, with no new adverse findings reported. These developments underscore AbbVie's commitment to enhancing treatment options for psoriatic arthritis.
AbbVie (NYSE: ABBV) presented new analyses of its medication RINVOQ® (upadacitinib) for treating moderate to severe atopic dermatitis at the EADV Virtual Congress. Key findings include that over 61% of patients on RINVOQ 30 mg achieved EASI 75 at week 16 compared to 11% on placebo, irrespective of demographics. Additionally, RINVOQ demonstrated superior efficacy against dupilumab in four body regions at week 16. The safety profile remained consistent with previous studies, with acne as the most common adverse event.
AbbVie (NYSE: ABBV) announced FDA approval for QULIPTA™ (atogepant), the first oral CGRP receptor antagonist for preventing episodic migraines in adults. Supported by robust clinical data, QULIPTA demonstrated significant reductions in monthly migraine days and was well tolerated among nearly 2,000 patients in trials. It aims to alleviate the substantial disability caused by migraines, which affect over 39 million people in the U.S. QULIPTA will be available in October 2021, complementing AbbVie's migraine treatment portfolio.
AbbVie (NYSE: ABBV) announced it will present 27 abstracts at the 30th EADV Congress from September 29 to October 2, 2021. Highlights include analyses on RINVOQ (upadacitinib) for atopic dermatitis and new data on SKYRIZI (risankizumab) for psoriasis and psoriatic arthritis. Key findings will come from Phase 3 trials, including a head-to-head study of RINVOQ vs. dupilumab, showcasing safety and efficacy. This reinforces AbbVie's commitment to enhancing care for chronic inflammatory diseases.
AbbVie announced the submission of an application to the FDA for risankizumab-rzaa, a new treatment for moderate to severe Crohn's disease in patients aged 16 and older. This drug, an IL-23 inhibitor, is backed by data from three Phase 3 trials: ADVANCE, MOTIVATE, and FORTIFY. In these studies, patients treated with risankizumab-rzaa showed significantly greater clinical remission and endoscopic response compared to placebo. The therapy aims to address the unmet need for lasting remission in Crohn's patients, as highlighted by AbbVie’s senior VP of research.
AbbVie has submitted applications to the FDA and EMA for upadacitinib (15 mg, 30 mg, and 45 mg) for treating adults with moderately to severely active ulcerative colitis. These submissions are based on positive results from two Phase 3 induction studies and one maintenance study, where upadacitinib showed significant improvement in clinical remission compared to placebo. Additionally, the safety profile was consistent with existing data, with no new risks identified. This treatment could provide a new option for patients who have not responded adequately to current therapies.
AbbVie and REGENXBIO announced a partnership to develop RGX-314, a gene therapy for wet age-related macular degeneration (AMD) and diabetic retinopathy (DR). REGENXBIO will complete ongoing trials, while AbbVie leads global development and commercialization. AbbVie will pay REGENXBIO $370 million upfront, with potential total payments of up to $1.38 billion based on milestones. They will share profits from U.S. sales equally, with AbbVie paying tiered royalties internationally. The deal is expected to close by the end of 2021, contingent on regulatory approvals.
AbbVie Inc. (NYSE: ABBV) has declared a quarterly cash dividend of $1.30 per share, payable on November 15, 2021, to stockholders of record by October 15, 2021. Since its inception in 2013, AbbVie has increased its dividend by 225% and is recognized as a member of the S&P Dividend Aristocrats Index, highlighting its commitment to consistent annual dividend increases over at least 25 consecutive years.
